WO1995012407A1 - A pharmaceutical composition for the treatment of coronary thrombosis - Google Patents

A pharmaceutical composition for the treatment of coronary thrombosis Download PDF

Info

Publication number
WO1995012407A1
WO1995012407A1 PCT/DK1994/000414 DK9400414W WO9512407A1 WO 1995012407 A1 WO1995012407 A1 WO 1995012407A1 DK 9400414 W DK9400414 W DK 9400414W WO 9512407 A1 WO9512407 A1 WO 9512407A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasminogen
lys
body weight
treatment
effective amount
Prior art date
Application number
PCT/DK1994/000414
Other languages
English (en)
French (fr)
Inventor
Claus Bregengaard
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU80581/94A priority Critical patent/AU8058194A/en
Publication of WO1995012407A1 publication Critical patent/WO1995012407A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Definitions

  • the present invention relates to a method of treating coronary thrombosis, a method of preventing reocclusion of coronary arteries, as well as a pharmaceutical composition for use in the methods.
  • plasminogen activators such as urokinase, streptokinase and tissue plasminogen activator as the sole fibrinolytic agents in the treatment of thrombosis is well known, for instance as reviewed in E.J. Topol, "Advances in Thrombolytic Therapy for Acute Myocardial Infarction", J. Clin. Pharmacol.27, 1987, pp. 735-745; N.J. Marder and S. Sherry, "Thrombolytic Therapy: Current Status". New England J. Med. 318. 1988, pp. 1585-1595; J.
  • the present invention relates to a method of treating coronary thrombosis, the method comprising administering, to a patient in need of such treatment, an effective amount of lys-plasminogen and, simultaneously or sequentially, an effective amount of tissue plaminogen activator (t-PA).
  • tissue plaminogen activator t-PA
  • accelarated thrombolysis and prevention of reocclusion may furthermore result in decreased secondary restenosis in the vessels due to shorter exposure to the vessel wall to inducers of cell proliferation known to be produced by the thrombi (for instance PDGF, thrombin, etc.).
  • the present invention therefore relates to a method of preventing reocclusion of coronary arteries following treatment of coronary thrombosis, the method comprising administering, to a patient in need of such treatment, an effective amount of lys-plasminogen and, simultaneously or sequentially, an effective amount of tissue plaminogen activator (t-PA).
  • t-PA tissue plaminogen activator
  • the invention relates to a pharmaceutical composition for the treatment of coronary thrombosis, the composition comprising, in separate containers, lys-plasminogen and t-PA, each together with a pharmaceutically acceptable carrier or diluent.
  • the invention relates to the use of lys-plasminogen in combination with t-PA for the preparation of a medicament for the treatment of coronary thrombosis as well as for the prevention of reocclusion of coronary arteries following such treatment.
  • Lys-plasminogen for use according to the present invention may be prepared from native plasminogen (glu-plasminogen) by brief exposure of glu-plasminogen to plasmin resulting in cleavage of 77 amino-terminal amino acids and the formation of lys- plasminogen (named for the N-terminal lysine).
  • Native human plasminogen may be purified from plasma by several methods. Recent methods of purification from human plasma are based on affinity chromatography as described by D.G. Deutsch and E.T.Mertz, Fed. Proc. 29, 1979, p. 647, and Science 170. 1970, pp. 1095-1096.
  • An affinity matrix (lysine-Sepharose ® ) is prepared by covalent coupling of the ⁇ -amino group of L-lysine to Sepharose ® .
  • Plasma diluted with water is passed through a lysine-Sepharose ® column equilibrated with phosphate buffer (pH7.4) at room temperature after which the column is washed with phosphate buffer.
  • Plasminogen is then eluted with 0.2 M e -amino caproic acid (pH 7.4).
  • the e -amino caproic acid is then removed from plasminogen in the cold, by gel filtration on Sephadex ® equilibrated with phosphate buffer.
  • the use of human proteins purified from human plasma involves a certain risk of viral infection.
  • the risk of HIV and hepatitis infections has become a major concern in dealing with plasma-derived human proteins.
  • cDNA 5 sequences encoding plasminogen and lys-plasminogen as well as the preparation thereof are described in EP 319 944 (Zymogenetics).
  • t-PA it is preferred to produce the t-PA to be used according to the present invention by recombinant DNA techniques.
  • cDNA encoding t-PA has been described by Pennica et al., Nature 301. 1983, pp. 214-221; Kaufman et al., Mol. Cell. Biol. 5,
  • t-PA analogue may be used according to the invention.
  • Examples of t-PA analogues are described in, e.g. D.L. Higgins and W.F. Bennett, Ann. Rev. Pharmacol. Toxicol. 30, 1990, pp. 91-121; L. Pierard and A. Bollen, Biotechnology 15, 1990, pp. 283-304; and H. Pannekoek et al., Fibrinolysis 2, 1988, pp.
  • the DNA coding for the desired polypeptide may be introduced into a suitable recombinant expression vector.
  • This may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which 20 it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the DNA sequence encoding the desired polypeptide should be operably connected to a suitable promoter sequence.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • suitable promoters for directing the transcription of the DNA encoding the desired polypeptide in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.
  • a suitable promoter for use in insect cells is the polyhedrin promoter (Vasuvedan et al., FEBS Lett. 311, (1992) 7 - 11).
  • Suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080; Alber and Kawasaki, J. Mol. Appl. Gen.
  • Suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the tpjA promoter.
  • the DNA sequence encoding the desired polypeptide may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPIl (Alber and Kawasaki, op ⁇ cit.) or ADH3 (McKnight et al., op. cit.) terminators.
  • the vector may further comprise elements such as polyadenylation signals (e.g. from SV40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).
  • the recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • a DNA sequence enabling the vector to replicate in the host cell in question.
  • An example of such a sequence is the SV40 origin of replication.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hygromycin or methotrexate.
  • DHFR dihydrofolate reductase
  • the host cell into which the expression vector is introduced may be any cell which is capable of producing the desired polypeptide and may suitably be a eukaryotic cell, such as invertebrate (insect) cells or vertebrate cells, e.g. Xenopus laevis oocytes or mammalian cells, in particular insect and mammalian cells.
  • a eukaryotic cell such as invertebrate (insect) cells or vertebrate cells, e.g. Xenopus laevis oocytes or mammalian cells, in particular insect and mammalian cells.
  • suitable mammalian cell lines are the COS (ATCC CRL 1650), BHK (ATCC CRL 1632, ATCC CCL 10), CHL (ATCC CCL39) or CHO (ATCC CCL 61) cell lines.
  • fungal cells may be used as host cells of the invention.
  • suitable yeasts cells include cells of Saccharomyces spp. or Schizosaccharomyces spp., in particular strains of Saccharomyces cerevisiae.
  • Other fungal cells are cells of filamentous fungi, e.g. Aspergillus spp. or Neurospora spp., in particular strains of Aspergillus oryzae or Aspergillus niger.
  • Aspergillus spp. for the expression of proteins is described in, e.g., EP 238 023.
  • the desired polypeptide may then be produced by a method which comprises culturing a cell as described above in a suitable nutrient medium under conditions which are conducive to the expression of the desired polypeptide and recovering the resulting polypeptide from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).
  • lys-plasminogen or glu-plasminogen may be produced by coexpression of lys- or glu-plasminogen with ⁇ -2-plasmin inhibitor or ⁇ -1-antitrypsin (AAT) in transfected BHK cells.
  • AAT ⁇ -2-plasmin inhibitor or ⁇ -1-antitrypsin
  • Coexpression with AAT causes inhibition of urokinase produced by the BHK cells.
  • Activation of plasminogen by urokinase and plasmin-mediated proteolytic cleavage is thereby greatly reduced and consequently, high levels of intact plasminogen is obtained.
  • the polypeptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, affinity chromatography, or the like.
  • a salt e.g. ammonium sulphate
  • purification a variety of chromatographic procedures, e.g. ion exchange chromatography, affinity chromatography, or the like.
  • the pharmaceutical composition of the invention may be compounded in any form suitable for parenteral administration (i.e. for intravenous injection or infusion), for instance by dissolving or suspending lys-plasminogen and t-PA, respectively, in sterile water or isotonic saline.
  • the suitable dosage of lys-plasminogen may be in the range of 0.1-3.0 mg/kg body weight, preferably 0.3-1.5 mg/kg body weight, more preferably about 1 mg/kg body weight, dependent on the severity of the condition, the age and general health of the patient to whom the composition is administered, etc.
  • a corresponding suitable dosage of t-PA is one which is capable of activating the lys- plasminogen administered to the patient.
  • the dosage of t-PA co-administered with lys-plasminogen may suitably be in the range of 0.2-2.0 mg/kg body weight, preferably 0.3-1.5 mg/kg body weight, more preferably about 1 mg/kg body weight.
  • the unit dosage of lys-plasminogen in the composition will typically be in the range of 20-100 mg, and the unit dosage of t-PA will typically be in the range of 20-100 mg.
  • the administration of lys- plasminogen may be substantially simultaneous with the administration of t-PA. This may, for instance, be effected by providing lys-plasminogen and t-PA in a device which makes it possible to administer two substances simultaneously.
  • lys- plasminogen or t-PA may be administered first and the other component may be administered immediately after that ("immediately” meaning any period of time up to one minute after administration of the first component).
  • t-PA may be administered before the administration of lys- plasminogen.
  • lys-plasminogen may be administered before the administration of t-PA.
  • the t-PA may be adminstered 5-20 minutes, preferably about 10 minutes, after the administration of lys-plasminogen.
  • the present invention relates to the use of lys-plasminogen in combination with t-PA for the preparation of a medicament for the treatment of coronary thrombosis.
  • the lys-plasminogen and t-PA are provided in separate containers in a form adapted to the simultaneous or sequential co- administration of lys-plasminogen and t-PA.
  • Recombinant human lys-plasminogen was expressed in BHK cells substantially as described in EP 319 944 and purified by the method described in PCT/DK93/00206.
  • the purified product was freeze-dried by conventional methods.
  • the freeze-dried lys- plasminogen was stored in vials containing 50 mg protein per vial.
  • T-PA was obtained from Boehringer Ingelheim.
  • Myocardial shortening fraction at 2 hours after t-PA infusion in the LAD supplied region in lys-plasminogen-treated dogs was +1 +/-1% (vs. -10 +/-5% in saline-treated dogs, P ⁇ 0.01). Plasma fibrinogen levels were lower in lys-plasminogen-treated dogs (0.3
  • lys-plasminogen administered before t-PA reduces the time to restoration of flow, sustains the restored flow and preserves myocardial function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/DK1994/000414 1993-11-05 1994-11-03 A pharmaceutical composition for the treatment of coronary thrombosis WO1995012407A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU80581/94A AU8058194A (en) 1993-11-05 1994-11-03 A pharmaceutical composition for the treatment of coronary thrombosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK1256/93 1993-11-05
DK931256A DK125693D0 (enrdf_load_stackoverflow) 1993-11-05 1993-11-05

Publications (1)

Publication Number Publication Date
WO1995012407A1 true WO1995012407A1 (en) 1995-05-11

Family

ID=8102801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1994/000414 WO1995012407A1 (en) 1993-11-05 1994-11-03 A pharmaceutical composition for the treatment of coronary thrombosis

Country Status (5)

Country Link
AU (1) AU8058194A (enrdf_load_stackoverflow)
DK (1) DK125693D0 (enrdf_load_stackoverflow)
IL (1) IL111501A0 (enrdf_load_stackoverflow)
WO (1) WO1995012407A1 (enrdf_load_stackoverflow)
ZA (1) ZA948721B (enrdf_load_stackoverflow)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035117A1 (en) * 1994-06-17 1995-12-28 British Biotech Pharmaceuticals Limited Thrombolytic composition
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778320A (zh) * 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
EP3395359A4 (en) * 2015-12-18 2019-06-12 Talengen International Limited PROCESS FOR PREVENTING OR TREATING ACUTE AND CHRONIC THROMBOSE
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352897A1 (en) * 1988-06-20 1990-01-31 The Wellcome Foundation Limited TPA-containing medicaments
WO1991015235A1 (en) * 1990-03-30 1991-10-17 Survival Technology, Inc. t-PA ENHANCER PROFILE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352897A1 (en) * 1988-06-20 1990-01-31 The Wellcome Foundation Limited TPA-containing medicaments
WO1991015235A1 (en) * 1990-03-30 1991-10-17 Survival Technology, Inc. t-PA ENHANCER PROFILE

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, Volume 88, No. 4, October 1993, J.L. METHA et al., "Lys-Plasminogen Improves the Quality of Tissue-Plasminogen Activator-Induced Coronary Thrombolysis in Dogs", page 616. *
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 06981990, Medline Accession No. 89283990, LJUNGBERG J. et al., "Potentiated Thrombolysis in a Chandler System Using rtPA and Lys-Plasminogen"; & THROMB. RES., 15 Mar. 1989, 53 (6), p569-76. *
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 07079611, Medline Accession No. 89381611, MARCON J.L., "Local Thrombolysis Using a Combination of RTPA and Lys-Plasminogen in Ischemia Due to a Previous Thrombosisa"; & J. MAL. VASC., 1989, 14 (3), p265-6. *
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 07374315, Medline Accession No. 90281315, GAO S.W. et al., "Differential Effect of Platelets on Plasminogen Activation by Tissue Plasminogen Activator, Urokinase and Streptokinase"; & THROMB. RES., 15 May 1990, 58 (4), p421-33. *
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 08041983, Medline Accession No. 92179983, NISHINO N. et al., "Influence of Intrinsic and Extrinsic Plasminogen Upon the Lysis of Thrombi in Vitro"; & THROMB. HAEMOST., 2 Dec. 1991, 66 (6), p672-7. *
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 09063195, Medline Accession No. 94378195, CHEN LY et al., "Lys- and Glu-Plasminogen Potentiate the Inhibitory Effect of Recombinant Tissue Plasminogen Activator on Human Platelet Aggregation"; & THROMB. RES., 15 Jun. 1994, 74 (6), p555-63. *
DIALOG INFORMATION SERVICES, File 5, BIOSIS, Dialog Accession No. 11014906, Biosis No. 97214906, CHEN L. et al., "Lys-Plasminogen, But Not Glu-Plasminogen, Improves The Quality of Tissue-Plasminogen Activator-Induced Coronary Thrombolysis in Dogs"; & COLLEGE OF CARDIOLOGY, March 13-17, 1994. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035117A1 (en) * 1994-06-17 1995-12-28 British Biotech Pharmaceuticals Limited Thrombolytic composition
US5741771A (en) * 1994-06-17 1998-04-21 British Biotech Pharmaceuticals Ltd. Thrombolytic composition
US10864257B2 (en) 2015-12-18 2020-12-15 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
CN108778320A (zh) * 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
EP3395359A4 (en) * 2015-12-18 2019-06-12 Talengen International Limited PROCESS FOR PREVENTING OR TREATING ACUTE AND CHRONIC THROMBOSE
EP3391902A4 (en) * 2015-12-18 2019-06-12 Talengen International Limited Novel method for preventing and treating cardiovascular diseases
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof

Also Published As

Publication number Publication date
ZA948721B (en) 1995-05-08
AU8058194A (en) 1995-05-23
IL111501A0 (en) 1995-01-24
DK125693D0 (enrdf_load_stackoverflow) 1993-11-05

Similar Documents

Publication Publication Date Title
RU2166326C2 (ru) Комбинация тромболитически активных белков и антикоагулянтов
JP2631645B2 (ja) 新規化合物、その製法及びそれを含む医薬組成物
AU600724B2 (en) Novel combination
EP2760887B1 (en) Compositions and methods for modulating hemostasis
JPH03500724A (ja) 組織プラスミノーゲン活性化因子の誘導体
US8212003B2 (en) Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof
US4976959A (en) T-PA and SOD in limiting tissue damage
EP0307847B1 (en) Thrombolytic agent
WO1995012407A1 (en) A pharmaceutical composition for the treatment of coronary thrombosis
US5747291A (en) Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect
US7070958B2 (en) Methods of making pro-urokinase mutants
EP0357296A1 (en) Combination of t-PA and protein C
EP0304311A1 (en) Complex of polyethylene glycol and tissue plasminogen activator
JP2012077090A (ja) 脳梗塞の処置のための非神経毒性プラスミノーゲン活性剤の静脈内注射
JP2942578B2 (ja) 新しい結合特性を有する超酸化物不均化酵素類縁体
US5342616A (en) Method of administering tissue plasminogen activator
US20010046495A1 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
CA2086835C (en) Tissue plasminogen activator variants with decreased clearance
JPH08504575A (ja) トロンビン活性化プラスミノーゲン誘導体
EP0352897B1 (en) Tpa-containing medicaments
US5908625A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
AU627927B2 (en) Pharmaceutical compositions
CN101848928B (zh) 葡激酶变异体
JPS6338327B2 (enrdf_load_stackoverflow)
JPH08268910A (ja) プロテインｃの皮下投与のための薬剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN CZ FI HU JP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA